Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
As pivotal data approach, the French group pays $210m for ex-US rights.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
